The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2023 | Preoperative chemoimmunotherapy: what this means for surgery
Jonathan Spicer, BSc (Hon), MD, PhD, FRCS, McGill University, Montreal, Canada, outlines how the employment of surgery as a treatment is adjusting to meet the positive outcomes associated with preoperative chemoimmunotherapy. He notes that the favored minimally invasive surgery techniques can still be employed in settings where patients are prescribed preoperative chemoimmunotherapy, despite the extra challenges that this can pose. This therapy also provides an opportunity to significantly reduce the extent of the surgery performed, or potentially rule out the need for surgery entirely in select patients. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
